SCHEMBL4345893

SCHEMBL4345893

Cn1ncc2nc(-c3ccc(F)cc3)n(NCc3ccc(Br)cc3)c(=O)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
BRD4 O60885 2/20 0.41
KAT2B Q92831 1/20 0.41
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
THRB P10828 1/20 0.37
CES2 O00748 1/20 0.35
TP53 P04637 2/20 0.35
PARP1 P09874 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
ALDH1A1 P00352 4/20 0.34
CYP1A2 P05177 4/20 0.34
GAA P10253 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
RAB9A P51151 1/20 0.34
HTR2C P28335 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338997 0.90 BRD4 (0.46) SMN1; SMN2BRD4KAT2BMAPTTHRB
SCHEMBL4349060 0.87 SMN1; SMN2 (0.42) SMN1; SMN2BRD4KAT2BMAPTNPSR1
SCHEMBL4353820 0.80 SMN1; SMN2 (0.38) SMN1; SMN2MAPTNPSR1CES2TP53
SCHEMBL4236185 0.79 SMN1; SMN2 (0.67) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4242353 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4233963 0.78 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1TP53ALDH1A1
SCHEMBL4201370 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2
SCHEMBL4735977 0.77 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1TP53PARP1
SCHEMBL4201369 0.77 SMN1; SMN2 (0.44) SMN1; SMN2MAPTNPSR1CES2TP53
SCHEMBL4195763 0.76 SMN1; SMN2 (0.48) SMN1; SMN2MAPTNPSR1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 SMN1; SMN2 3183/4885BRD4 2047/4885KAT2B 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.